At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 61 enrolled
Drug / intervention
Immediate Release (IR) Formulation +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
In Brief
A Phase 1 clinical trial evaluating Immediate Release (IR) Formulation, Gastro-Retentive (GR) Formulation, and 2 other interventions for Relapsed or Refractory Multiple Myeloma. Completed, enrolled 61 participants across 20 sites in 4 countries.
Detailed Summary
A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in participants with relapsed refractory multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed or Refractory Multiple Myeloma
CountriesAustralia, Canada, Spain, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartJan 2017
Primary CompletionOct 2022
TodayJul 2026
First PostedOct 19, 2016
Enrollment StartJan 17, 2017
Primary CompletionOct 6, 2022
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 9.7 years ago
Interventions
Immediate Release (IR) Formulationdrug
Immediate Release (IR) Formulation
Gastro-Retentive (GR) Formulationdrug
Gastro-Retentive (GR) Formulation
Dexamethasonedrug
Dexamethasone
Pomalidomidedrug
Pomalidomide